CASI Pharmaceuticals Wins Emergency Relief Regarding the Dispute with Juventas Cell Therapy Ltd Prohibiting Juventas from Commercializing CNCT19
On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company (“CASI” or the “Company”) announced that, with respect to the Company’s previously announced dispute